These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 32351687)
1. Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells. Pungsrinont T; Sutter MF; Ertingshausen MCCM; Lakshmana G; Kokal M; Khan AS; Baniahmad A Cell Biosci; 2020; 10():59. PubMed ID: 32351687 [TBL] [Abstract][Full Text] [Related]
2. Androgen-Induced MIG6 Regulates Phosphorylation of Retinoblastoma Protein and AKT to Counteract Non-Genomic AR Signaling in Prostate Cancer Cells. Schomann T; Mirzakhani K; Kallenbach J; Lu J; Rasa SMM; Neri F; Baniahmad A Biomolecules; 2022 Jul; 12(8):. PubMed ID: 36008945 [TBL] [Abstract][Full Text] [Related]
3. The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells. Mirzakhani K; Kallenbach J; Rasa SMM; Ribaudo F; Ungelenk M; Ehsani M; Gong W; Gassler N; Leeder M; Grimm MO; Neri F; Baniahmad A Oncogene; 2022 Feb; 41(7):943-959. PubMed ID: 34667276 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer. Kokal M; Mirzakhani K; Pungsrinont T; Baniahmad A Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32650419 [TBL] [Abstract][Full Text] [Related]
5. The clock gene BHLHE40 and atypical CCNG2 control androgen-induced cellular senescence as a novel tumor suppressive pathway in prostate cancer. Heidari Horestani M; Atri Roozbahani G; Baniahmad A J Exp Clin Cancer Res; 2024 Jun; 43(1):174. PubMed ID: 38902772 [TBL] [Abstract][Full Text] [Related]
6. The protein composition of exosomes released by prostate cancer cells is distinctly regulated by androgen receptor-antagonists and -agonist to stimulate growth of target cells. Atri Roozbahani G; Kokal-Ribaudo M; Heidari Horestani M; Pungsrinont T; Baniahmad A Cell Commun Signal; 2024 Apr; 22(1):219. PubMed ID: 38589887 [TBL] [Abstract][Full Text] [Related]
7. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy. Carpenter V; Saleh T; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA Biochem Pharmacol; 2021 Nov; 193():114765. PubMed ID: 34536356 [TBL] [Abstract][Full Text] [Related]
8. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells. Hessenkemper W; Roediger J; Bartsch S; Houtsmuller AB; van Royen ME; Petersen I; Grimm MO; Baniahmad A Mol Endocrinol; 2014 Nov; 28(11):1831-40. PubMed ID: 25203674 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells. Gupta S; Pungsrinont T; Ženata O; Neubert L; Vrzal R; Baniahmad A Horm Cancer; 2020 Aug; 11(3-4):182-190. PubMed ID: 32562083 [TBL] [Abstract][Full Text] [Related]
10. Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway. Roediger J; Hessenkemper W; Bartsch S; Manvelyan M; Huettner SS; Liehr T; Esmaeili M; Foller S; Petersen I; Grimm MO; Baniahmad A Mol Cancer; 2014 Sep; 13():214. PubMed ID: 25216853 [TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation-induced senescence confers sensitivity to a senolytic strategy in prostate cancer. Carpenter V; Saleh T; Chakraborty E; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA Biochem Pharmacol; 2024 Aug; 226():116385. PubMed ID: 38909784 [TBL] [Abstract][Full Text] [Related]
13. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells. Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046 [TBL] [Abstract][Full Text] [Related]
14. Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation. Xu H; Sun Y; Huang CP; You B; Ye D; Chang C Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235588 [TBL] [Abstract][Full Text] [Related]
15. The senolytic agent ABT263 ameliorates osteoporosis caused by active vitamin D insufficiency through selective clearance of senescent skeletal cells. Yang C; Qiao W; Xue Q; Goltzman D; Miao D; Dong Z J Orthop Translat; 2024 Nov; 49():107-118. PubMed ID: 39430127 [TBL] [Abstract][Full Text] [Related]
16. DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity. Malaquin N; Vancayseele A; Gilbert S; Antenor-Habazac L; Olivier MA; Ait Ali Brahem Z; Saad F; Delouya G; Rodier F Cells; 2020 Jul; 9(7):. PubMed ID: 32630281 [TBL] [Abstract][Full Text] [Related]
17. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75. Hu WY; Xu L; Chen B; Ou S; Muzzarelli KM; Hu DP; Li Y; Yang Z; Vander Griend DJ; Prins GS; Qin Z Prostate; 2019 Jul; 79(10):1166-1179. PubMed ID: 31135075 [TBL] [Abstract][Full Text] [Related]
18. Cellular senescence imaging and senolysis monitoring in cancer therapy based on a β-galactosidase-activated aggregation-induced emission luminogen. Cen P; Cui C; Huang J; Chen H; Wu F; Niu J; Zhong Y; Jin C; Zhu WH; Zhang H; Tian M Acta Biomater; 2024 Apr; 179():340-353. PubMed ID: 38556136 [TBL] [Abstract][Full Text] [Related]
19. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814 [TBL] [Abstract][Full Text] [Related]
20. Nintedanib induces senolytic effect via STAT3 inhibition. Cho HJ; Hwang JA; Yang EJ; Kim EC; Kim JR; Kim SY; Kim YZ; Park SC; Lee YS Cell Death Dis; 2022 Sep; 13(9):760. PubMed ID: 36055997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]